相关临床试验
5
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
20.0%
已完成
1
20.0%
招募中
2
40.0%
撤回
1
20.0%
暂无批准数据
- A genome-wide study in Danish blood donor and patient cohorts maps the genetic architecture of cytokine autoantibodies and their links to common disease risk. - The research leverages the DBDS and CHB cohorts, supported by Bio- and Genome Bank Denmark and the Novo Nordisk Foundation. - Findings may clarify how naturally occurring anti-cytokine antibodies influence susceptibility to inflammatory and other common conditions. - The work was conducted with infrastructure from Rigshospitalet, Copenhagen University Hospital, and the Department of Clinical Immunology.
- Gabather has launched the TOTEMS phase II clinical trial evaluating drug candidate GT-002 in patients with schizophrenia spectrum disorders at Copenhagen University Hospital. - The study is designed as a double-blind, randomized trial including both schizophrenia patients and healthy controls with continuous data readout capabilities. - CEO Michael-Robin Witt has expressed hopes of publishing an interim report this autumn, marking a significant milestone for the company's psychiatric drug development program. - The company has also filed a patent for a new non-sedating sleep treatment and entered partnerships aimed at facilitating licensing discussions.
- Recent randomized controlled trials present conflicting evidence on left bundle branch area pacing (LBBAP) versus traditional biventricular pacing for cardiac resynchronization therapy, with operator experience emerging as a critical factor. - The LECART trial demonstrated superior outcomes with LBBAP, primarily driven by reduced device-related complications requiring surgical reintervention, while the LEFT-BUNDLE-CRT trial failed to establish noninferiority. - Extended follow-up data from multiple studies suggest that while conduction-system pacing shows promise, biventricular pacing remains the established first-line therapy with the strongest evidence base. - Expert consensus indicates the field is moving toward individualized CRT approaches based on anatomy, conduction patterns, and operator expertise rather than universal replacement of conventional therapy.
- A secondary analysis of the DANFLU-2 trial involving over 332,000 older adults found that high-dose influenza vaccines reduced hospitalizations for cardiorespiratory disease, cardiovascular disease, and influenza compared to standard-dose vaccines. - The protective benefits were consistent in adults with and without diabetes, though people with diabetes experienced greater absolute benefit due to their higher baseline risk for flu-related complications. - High-dose vaccination showed enhanced protection in individuals with diabetes of longer duration (five years or more) and those with diabetes-related complications, suggesting potential for targeted prevention strategies. - The high-dose vaccine contains four times the antigen levels of standard vaccines and demonstrated relative vaccine effectiveness of 41.6% against influenza hospitalizations in diabetic patients versus 44.3% in non-diabetic patients.
- Ustekinumab showed significantly superior drug survival compared to adalimumab and secukinumab among biologic-naïve psoriasis patients, with a 5-year discontinuation risk of 37% versus 51% and 54% respectively. - Among bio-experienced patients, newer biologics including guselkumab, bimekizumab, and risankizumab demonstrated the highest 2-year drug survival rates compared to ustekinumab. - The nationwide Danish cohort study analyzed 4,438 psoriasis patients from DERMBIO registry, providing real-world evidence on treatment persistence across eight different biologic therapies. - A separate phase 3 trial confirmed that ustekinumab biosimilar DMB-3115 demonstrated comparable efficacy and safety to reference ustekinumab through 52 weeks in moderate to severe plaque psoriasis.
- IO Biotech published five-year follow-up data from its Phase 1/2 MM1636 trial showing IO102-IO103 combined with nivolumab achieved a median progression-free survival of 25.5 months in metastatic melanoma patients. - The study demonstrated a median duration of response exceeding 53 months and median overall survival of 60 months, with vaccine-specific immune biomarkers suggesting distinct immune modulation not seen with anti-PD-1 monotherapy. - These results supported FDA Breakthrough Therapy Designation and provided the foundation for IO Biotech's Phase 3 trial IOB-013/KN-D18, which completed enrollment with 407 patients in December 2023.
- A Danish registry study of over 34,000 postmenopausal women found that vaginal estrogen tablets were not associated with increased risk of recurrent ischemic stroke in women with prior stroke history. - The research addresses a critical knowledge gap for a vulnerable population often excluded from hormone therapy studies, examining women aged 45 and older who had experienced their first stroke between 2008-2017. - Unlike systemic hormone replacement therapy which is contraindicated after stroke, vaginal estrogen tablets showed no significant association with stroke recurrence across current, recent, or past use categories. - The findings may reassure healthcare providers treating menopausal symptoms in stroke survivors, though researchers emphasize the need for cautious interpretation of real-world data.
- A new study indicates that the antidepressant escitalopram (Lexapro) may improve memory and cognitive skills in patients. - The research links escitalopram's cognitive benefits to increased activity in the brain's 5HT4 serotonin receptor. - Cognitive tests showed improved recall ability in patients treated with escitalopram for eight weeks, correlating with enhanced 5HT4 receptor function. - Future research will explore drugs specifically targeting the 5HT4 receptor to treat cognitive impairments, regardless of depression symptoms.
